Sidera Bio is a clinical stage company licensing a modulator of metabolism, inflammation and fibrosis to develop therapies for chronic kidney disease (CKD) and other indications where fibrosis is a significant part of the disease. The lead program combines three drug mechanisms into a single asset, with clinical trials currently being conducted in kidney and liver disease.​

Sidera’s underlying platform is set to identify therapeutic targets for cardiometabolic disease based on genetic insights for disease pathogenesis.

‍

‍